HEALTH OF WOMAN. 2020.3(149): 42-47; doi 10.15574/HW.2020.149.42
Konkov D. G.
Vinnytsia regional clinical hospital named after. M. I. Pirogov

The main role in maintaining the constancy of the vaginal microbiota belongs to lactobacilli, which perform a barrier function, prevent the spreading of opportunistic pathogens and appearance of pathogenic microorganisms due to the production of hydrogen peroxide, lactic acid, bacteriocins, and endobiotics. The estrogen-dependent ability of lactobacilli to adhere to vaginal epithelial cells helps them to provide colonization resistance to the vaginal microbiota. Along with the difficulties in treating vaginal infections in women during pregnancy, which are associated with the restriction of the use of antibacterial medications, one of the causes of relapse of genital infections can be considered the absence or inadequate correction of vaginal microbiocenosis.
The literature review presents current data on the prevention and treatment of dysbiotic disorders in obstetric practice. Attention is paid to the clinical features of the use of probiotics during pregnancy. Questions on the ability of probiotics to prevent the development of «great obstetrical syndromes» and to prevent early neonatal complications are considered to.
Key words: vaginal microbiota, miscarriage, preterm birth, preeclampsia, probiotics, Lactobacillus rhamnosus, Lactobacillus gasseri.

REFERENCES

1. Ajlamazyan EK, Shipicyna EV, Savicheva AM. 2016. Mikrobiota zhenshchiny i iskhody beremennosti. Zhurnal akusherstva i zhenskih boleznej 65(4):6-14.

2. Bondarenko KR. 2015. Pozdnie akusherskie oslozhneniya, associirovannye s gramotricatel'nymi bakterial'nymi infekciyami. Patogenez, klinika, diagnostika i profilaktika. Moskva:48.

3. Bondarenko KR, Dobrohotova YUE, Novik MYU. 2017. Vozmozhnosti profilaktiki pozdnih akusherskih oslozhnenij putem korrekcii endogennoj mikrobioty. Medicinskij alfavit 3(23):6-14.

4. Bondarenko KR, Dobrohotova YUE. 2019. Sovremennye aspekty lecheniya otdel'nyh urogenital'nyh infekcij pri beremennosti. RMZH. Mat' i ditya. 2(3):168–72.

5. Glushanova NA. 2003. Biologicheskie svojstva laktobacill. Byulleten' sibirskoj mediciny 4:50-8.

6. Grafova ED. 2019. Kliniko-mikrobiologicheskoe obosnovanie differencirovannoj korrekcii mikrobiocenoza vlagalishcha u zhenshchin s cervikovaginal'nymi infekciyami v 1 trimestre beremennosti. CHelyabinsk:23.

7. Dolgushina VF, SHishkova YUS, Grafova ED, Zav'yalova SA, Kurnosenko IV, Vostrenkova SA. 2019. Korrekciya biocenoza vlagalishcha pri cervikovaginal'noj infekcii vo vremya beremennosti. Vestnik sovremennoj klinicheskoj mediciny 12(2): 33-6.

8. Dolgushina VF, SHishkova YUS, Grafova ED, Kurnosenko IV, Zav'yalova SA. 2018. Cervikovaginal'nye infekcii u zhenshchin v pervom trimestre beremennosti. Voprosy ginekologii, akusherstva i perinatologii 17(2):11–5.

9. Kira EF, Artymuk NV, Savicheva AM s soavt. 2015. Primenenie molochnoj kisloty v sochetanii s glikogenom dlya lecheniya bakterial'nogo vaginoza. Ginekologiya 2:93-6.

10. Konkov DH, Starovier AV, Bulavenko OV, Vozniuk AV. 2017. Klinichna efektyvnist vahinalnykh supozytoriiv, shcho mistiat miramistyn, u korystuvachiv akusherskoho pesariiu pry nespetsyfichnomu vahiniti. Zdorov'e zhenshchiny 7:2-7.

11. Ploskireva AA. 2018. Probioticheskaya terapiya: ot pokazanij k vyboru. RMZH 2(ll):100-1.

12. Plotko EE, Zornikov DL, Hayutin LV, Voroshilina ES. 2015. Disbioz vlagalishcha: vidovoj sostav laktoflory i vozmozhnosti nemedikamentoznoj korrekcii. Akusherstvo i ginekologiya 10:112-17.

13. Sinyakova AA. 2017. Sovremennye predstavleniya o mikrobiocenoze vlagalishcha i ego vliyanii na iskhody beremennosti. Zhurnal akusherstva i zhenskih boleznej 66(6):89–100.

14. Taran OA, Bulavenko OV, Konkov DH, Lobastova TV. 2018. Suchasnyi pohliad na optymalnu terapiiu VPL-asotsiiovanoi patolohii shyiky matky na tli vahinalnoho dysbiozu. Reproduktyvna endokrynolohiia 6(44):16-20.

15. Agerholm-Larsen L, Raben A, Haulrik N et al. 2000. Effect of 8 week intake of probiotic milk products on risk factors for cardiovascular diseases.Eur J Clin Nutr 54:288-97. https://doi.org/10.1038/sj.ejcn.1600937; PMid:10745279

16. Aihara K, Kajimoto O, Hirata H et al. 2005. Effect of powdered fermented milk with Lactobacillus helveticus on subjects with high-normal blood pressure or mild hypertension. J Am Coll Nutr 24:257-65. https://doi.org/10.1080/07315724.2005.10719473; PMid:16093403

17. Anukam KC, Osazuwa E, Osemene GI et al. 2006. Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect. 8:2772-6. https://doi.org/10.1016/j.micinf.2006.08.008; PMid:17045832

18. Boyle RJ, Mah LJ, Chen A et al. 2008. Effects of Lactobacillus GG treatment during pregnancy on the development of fetal antigen-specific immune responses. Clin. Exp. Allergy. 38:1882-1890. https://doi.org/10.1111/j.1365-2222.2008.03100.x; PMid:18823310

19. Coudeyras S, Jugie G, Vermerie M, Forestier C. 2008. Adhesion of human probiotic Lactobacillus rhamnosus to cervical and vaginal cells and interaction with vaginosis-associated pathogens. Infect Dis Obstet Gynecol.: 549-640. https://doi.org/10.1155/2008/549640; PMid:19190778 PMCid:PMC2631649

20. Daskalakis GJ, Karambelas AK. 2017. Vaginal Probiotic Administration in the Management of Preterm Premature Rupture of Membranes. Fetal Diagn Ther. 42(2):92-98. https://doi.org/10.1159/000450995; PMid:27744438

21. Donders GG, Van Calsteren K, Bellen G et al. 2009. Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. BJOG. 116(10):1315-24. https://doi.org/10.1111/j.1471-0528.2009.02237.x; PMid:19538417

22. Erwin Espinosa, MD; Philippines survey on the use of EcoVag vaginal capsule usage and acceptance and its effect on patients with Bacterial vaginosis. 2015:1-6.

23. Garland SM, Ni Chuileannain F, Satzke C, Robins-Browne R. 2002. Mechanisms and markers of infection in pregnancy. J Reprod Immunol. 57(1-2):169-83. https://doi.org/10.1016/S0165-0378(02)00018-9

24. Harold Marcotte, Kasper Krogh Andersen, Yin Lina, Fanglei Zuo, Zhu Zeng, Per Göran Larsson, Erik Brandsborg, Gunnar Brønstad, Lennart Hammarström. 2017. Characterization and complete genome sequences of L. rhamnosus DSM 14870 and L. gasseri DSM 14869 contained in the EcoVag® probiotic vaginal capsules. Microbiological Research 205:88-98. https://doi.org/10.1016/j.micres.2017.08.003; PMid:28942850

25. Heczko PB et al. 2015. Supplementation of standard antibiotic therapy with oral probiotics for bacterial and aerobic vaginitis: a randomised, double-blind, placebo-controlled trial. BMC Women's Health 15:115. https://doi.org/10.1186/s12905-015-0246-6; PMid:26635090 PMCid:PMC4669640

26. Jacobsson B, Mattsby-Baltzer I, Andersch B et al. 2003. Microbial invasion and cytokine response in amniotic fluid in a Swedish population of women with preterm prelabor rupture of membranes. Acta Obstet Gynecol Scand. 82:423-31. https://doi.org/10.1034/j.1600-0412.2003.00157.x; PMid:12752072

27. Konkov DG, Piskun AO, Taran OA, Kostur GV. 2020. Specialties of hystomorphometrical changes in placenta of women with early and late preeclampsia. Wiadomosci Lekarskie. 73(1):151-155.

28. Lamont RF, Sobel JD, Akins RA et al. 2011. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG. 118:533-49. https://doi.org/10.1111/j.1471-0528.2010.02840.x; PMid:21251190 PMCid:PMC3055920

29. Larsson PG et al. 2011. Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses. BMC Infectious Diseases 11:223. https://doi.org/10.1186/1471-2334-11-223; PMid:21854593 PMCid:PMC3176208

30. Machado D, Castro J, Palmeira-de-Oliveira A, Martinez-de-Oliveira J and Cerca N. 2016. Bacterial Vaginosis Biofilms: Challenges to Current Therapies and Emerging Solutions. Front. Microbiol. 6:1528. https://doi.org/10.3389/fmicb.2015.01528; PMid:26834706 PMCid:PMC4718981

31. Mancuso MS, Figueroa D, Szychowski JM et al. 2011. Midtrimester bacterial vaginosis and cervical length in women at risk for preterm birth. Am J Obstet Gynecol. 204:342. doi: 10.1016/j.ajog.2010.11.003. https://doi.org/10.1016/j.ajog.2010.11.003; PMid:21183154 PMCid:PMC3074251

32. Mastromarino P, Macchia S, Meggiorini L et al. 2009. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clin Microbiol Infect. 15:67-74. https://doi.org/10.1111/j.1469-0691.2008.02112.x; PMid:19046169

33. Menard JP, Bretelle F. 2012. Bacterial vaginosis and preterm delivery. Gynecologie, Obstetrique & Fertilite 40(1):48-54. https://doi.org/10.1016/j.gyobfe.2011.11.004; PMid:22192689

34. Mortaki D, Gkegkes ID, Psomiadou V, Blontzos N, Prodromidou A, Lefkopoulos F, Nicolaidou E. 2019. Vaginal microbiota and human papillomavirus: a systematic review. Journal of the Turkish German Gynecology Association. https://doi.org/10.4274/jtgga.galenos.2019.2019.0051; PMid:31564082

35. Nordqvist M, Jacobsson B, Brantsæter A-L et al. 2018. Timing of probiotic milk consumption during pregnancy and effects on the incidence of preeclampsia and preterm delivery: a prospective observational cohort study in Norway. BMJ Open 8:e018021. https://doi.org/10.1136/bmjopen-2017-018021; PMid:29362253 PMCid:PMC5780685

36. Norenhag J, Du J, Olovsson M, Verstraelen H , Engstrand L, Brusselaers N. 2020. The vaginal microbiota, human papillomavirus and cervical dysplasia: a systematic review and network meta-analysis. BJOG. 127(2):171-180. https://doi.org/10.1111/1471-0528.15854; PMid:31237400

37. Nivoliez A, Camares O, Paquet-Gachinat M. 2012. Influence of manufacturing processes on in vitro properties of the probiotic strain Lactobacillus rhamnosus Lcr35®. Journal of Biotechnology 160:236-241. https://doi.org/10.1016/j.jbiotec.2012.04.005; PMid:22542933

38. Othman M, Alfirevic Z, Neilson JP. 2007. Probiotics for preventing preterm labour. Cochrane Database Syst Rev. 24(1):CD005941. https://doi.org/10.1002/14651858.CD005941.pub2; PMid:17253567

39. Pandey N, Malik RK, Kaushik JK, Singroha G. 2013, Nov. Gassericin A: a circular bacteriocin produced by lactic acid bacteria Lactobacillus gasseri. World J Microbiol Biotechnol. 29(11):1977-87. https://doi.org/10.1007/s11274-013-1368-3; PMid:23712477

40. Parent D, Bossens M, Bayot D et al. 1996. Therapy of bacterial vaginosis using exogenously-applied Lactobacilli acidophili and a low dose of estriol: a placebo-controlled multicentric clinical trial. Arzneimittelforschung. 46:68-73.

41. Pelucchi C, Chatenoud L, Turati F, Galeone C et al. 2012. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiol. 23(3):402-414. https://doi.org/10.1097/EDE.0b013e31824d5da2; PMid:22441545

42. Polese B, Gridelet V, Araklioti E et al. 2014. The Endocrine Milieu and CD4 T-Lymphocyte Polarization during Pregnancy. Front Endocrinol. 5:106. https://doi.org/10.3389/fendo.2014.00106; PMid:25071722 PMCid:PMC4083450

43. Ravel J, Gajer P, Abdo Z et al. 2011. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA. 108:4680-7. https://doi.org/10.1073/pnas.1002611107; PMid:20534435 PMCid:PMC3063603

44. Reid G, Anukam K, James VI, van der Mei HC, Heineman C et al. 2005. Oral probiotics for maternal and newborn health. J Clin Gastroenterol 39;5:353-354. https://doi.org/10.1097/01.mcg.0000159268.58480.02; PMid:15815200

45. Reid JN, Bisanz JE, Monachese M et al. 2013. The rationale for probiotics improving reproductive healthand pregnancy outcome. Am J Reprod Immunol. 69(6):558-66. https://doi.org/10.1111/aji.12086; PMid:23414386

46. Stojanović N, Plećaš D, Plešinac S. 2012. Normal vaginal flora, disorders and application of probiotics in pregnancy. Arch Gynecol Obstet. 286(2):325-32. https://doi.org/10.1007/s00404-012-2293-7; PMid:22437191

47. Tan M, Zhu JC, Du J et al. 2011. Effects of probiotics on serum levels of Th1/Th2 cytokine and clinical outcomes in severe traumatic braininjured patients: a prospective randomized pilot study. Crit Care 15:R290. https://doi.org/10.1186/cc10579; PMid:22136422 PMCid:PMC3388628

48. VandeVusse L, Hanson L, Safdar N. 2013. Perinatal outcomes of prenatal probiotic and prebiotic administration: an integrative review. J. Perinat. Neonatal. Nurs. 27(4):288-301; https://doi.org/10.1097/JPN.0b013e3182a1e15d; PMid:24164813

49. Yang S, Li W, Challis JR et al. 2014. Probiotic Lactobacillus rhamnosus GR-1 supernatant prevents lipopolysaccharide-induced preterm birth and reduces inflammation in pregnant CD-1 mice. Am J Obstet Gynecol 211:44.e1-44.e12. https://doi.org/10.1016/j.ajog.2014.01.029; PMid:24486224

50. Zeng Z, Zuo F, Marcotte H. 2019. Putative adhesion factors in vaginal Lactobacillus gasseri DSM 14869: functional characterization. Appl Environ Microbiol. 85:e00800-19. https://doi.org/10.1128/AEM.00800-19; PMid:31420338 PMCid:PMC6752014